A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Everolimus (Primary) ; Anakinra; Denosumab
- Indications Cancer
- Focus Adverse reactions
- 05 Mar 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
- 05 Mar 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2020.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.